Hims & Hers Health (NYSE:HIMS) Shares Gap Down on Disappointing Earnings

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) gapped down before the market opened on Tuesday following a weaker than expected earnings announcement. The stock had previously closed at $29.14, but opened at $25.21. Hims & Hers Health shares last traded at $26.5740, with a volume of 14,767,725 shares traded.

The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The firm had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period last year, the business earned $0.20 earnings per share.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers raised its 2026 revenue outlook to $2.8 billion-$3.0 billion and guided Q2 revenue above Wall Street expectations, signaling management still sees strong demand ahead. Hims & Hers Health Misses Q1 CY2026 Sales Expectations, Stock Drops 11.5%
• Positive Sentiment: Needham lifted its price target on HIMS to $35 from $30 and reiterated a buy rating, suggesting some analysts still see upside after the pullback. Needham raises price target on Hims & Hers Health
• Neutral Sentiment: BTIG reaffirmed a neutral rating, reflecting a more cautious view as investors digest the mixed quarter and the company’s transition in its weight-loss business. BTIG reaffirms neutral rating on Hims & Hers Health
• Negative Sentiment: Hims & Hers reported a Q1 loss of $0.40 per share versus a profit a year ago, while revenue of $608.1 million missed estimates, disappointing investors who had expected stronger execution. Hims & Hers Health Q1 earnings report
• Negative Sentiment: Several reports said higher costs and the GLP-1 transition weighed on results, with the company posting a $92.1 million quarterly loss and weaker-than-expected first-quarter guidance implications. Reuters report on Hims & Hers quarterly results

Analyst Ratings Changes

A number of research firms have issued reports on HIMS. Truist Financial reiterated a “hold” rating and issued a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Needham & Company LLC lifted their price objective on Hims & Hers Health from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday. Evercore set a $24.00 target price on shares of Hims & Hers Health in a research note on Tuesday, February 24th. TD Cowen decreased their target price on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research report on Friday, March 27th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Friday, March 27th. Four analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus target price of $29.64.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Soleil Boughton sold 9,463 shares of Hims & Hers Health stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $30.00, for a total transaction of $283,890.00. Following the sale, the insider directly owned 299,368 shares in the company, valued at approximately $8,981,040. The trade was a 3.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 97,289 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the sale, the chief operating officer directly owned 407,282 shares in the company, valued at approximately $10,055,792.58. The trade was a 19.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 204,857 shares of company stock valued at $5,285,706 over the last quarter. 13.71% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. boosted its stake in Hims & Hers Health by 36.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 34,617 shares of the company’s stock valued at $719,000 after buying an additional 9,253 shares in the last quarter. Legacy Wealth Managment LLC ID acquired a new position in Hims & Hers Health during the first quarter worth $237,000. Swiss National Bank raised its stake in Hims & Hers Health by 1.1% during the first quarter. Swiss National Bank now owns 390,500 shares of the company’s stock worth $8,107,000 after acquiring an additional 4,300 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in Hims & Hers Health by 12.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 16,742 shares of the company’s stock worth $332,000 after acquiring an additional 1,799 shares in the last quarter. Finally, W.G. Shaheen & Associates DBA Whitney & Co lifted its holdings in shares of Hims & Hers Health by 109.2% during the first quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 14,427 shares of the company’s stock valued at $300,000 after acquiring an additional 7,532 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The company’s 50 day moving average price is $23.08 and its 200 day moving average price is $29.44. The company has a market cap of $5.95 billion, a price-to-earnings ratio of 50.98, a P/E/G ratio of 3.85 and a beta of 2.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.